Table 1 Clinical characteristics of TNBC patients according to expression of PDGFRβ and CDCP1
From: The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer
Overall cohort (N = 65b) | PDGFRβ pos (N = 29b) | PDGFRβ neg (N = 36b) | P valuec | CDCP1 pos (N = 37b) | CDCP1 neg (N = 28b) | P valuec | |
|---|---|---|---|---|---|---|---|
Age | |||||||
> = 50 years | 42 (64.6%) | 13 (44.8%) | 29 (80.6%) | 0,0040 | 22 (59.5%) | 20 (71.4%) | 0.4332 |
< 50 years | 23 (35.4%) | 16 (55.2%) | 7 (19.4%) | 15 (40.5%) | 8 (28.6%) | ||
Grade | |||||||
I, II | 9 (14.1%) | 0 (0%) | 9 (25.7%) | 0,0029 | 5 (13.5%) | 4 (14.8%) | 1.0000 |
III | 55 (85.9%) | 29 (100.0%) | 26 (74.3%) | 32 (86.5%) | 23 (85.2%) | ||
na | 1 | 1 | 1 | ||||
Necrosis | |||||||
No | 14 (22.2%) | 6 (20.7%) | 8 (23.5%) | 1,0000 | 6 (16.7%) | 8 (29.6%) | 0.2395 |
Yes | 49 (77.8%) | 23 (79.3%) | 26 (76.5%) | 30 (83.3%) | 19 (70.4%) | ||
na | 2 | 2 | 1 | 1 | |||
Multifocality | |||||||
No | 52 (82.5%) | 24 (82.8%) | 28 (84.4%) | 1,0000 | 28 (77.8%) | 24 (88.9%) | 0.3255 |
Yes | 11 (17.5%) | 5 (17.2%) | 6 (17.6%) | 8 (22.2%) | 3 (11.1%) | ||
na | 2 | 2 | 1 | 1 | |||
N positivity | |||||||
No | 38 (58.5%) | 17 (58.6%) | 21 (58.3%) | 1,0000 | 19 (51.4%) | 19 (67.9%) | 0.2117 |
Yes | 27 (41.5%) | 12 (41.4%) | 15 (41.7%) | 18 (48.6%) | 9 (32.1%) | ||
Size | |||||||
> 2 cm | 39 (60.9%) | 11 (39.3%) | 15 (41.7%) | 0,8035 | 15 (40.5%) | 10 (37.0%) | 0.8015 |
< = 2 cm | 25 (39.1%) | 18 (64.3%) | 21 (58.3%) | 22 (59.5%) | 17 (63.0%) | ||
na | 1 | 1 | 1 | ||||
DCISa | |||||||
No | 40 (63.5%) | 20 (68.9%) | 20 (58.9%) | 0,4424 | 23 (63.9%) | 17 (63.0%) | 1.0000 |
Yes | 23 (36.5%) | 9 (31.0%) | 14 (41.2%) | 13 (36.1%) | 10 (37.0%) | ||
na | 2 | 2 | 1 | 1 | |||